DGAP-News: AURELIUS becomes major player on the specialty chemical market
(firmenpresse) - DGAP-News: AURELIUS AG / Key word(s): Acquisition
AURELIUS becomes major player on the specialty chemical market
03.09.2012 / 09:00
---------------------------------------------------------------------
AURELIUS becomes major player on the specialty chemical market
Bayer CropScience Norwich production location becomes Briar Chemicals
- Acquisition completed with effect from September 1, 2012.
- Briar Chemicals becomes the third independent specialty chemical
subsidiary within the AURELIUS Group
- Further close cooperation planned with Bayer CropScience
Munich, September 3, 2012 - With the acquisition of the Norwich production
location from Bayer CropScience, the activities of the AURELIUS Group
(ISIN: DE000A0JK2A8) in the specialty chemical industry now rise to over
200 million euro in revenues. Starting September 1, 2012, the Norwich
facility will operate as Briar Chemicals Ltd., making crop protection and
specialty industrial chemicals. It is AURELIUS' third major acquisition in
the industry, after ISOCHEM/FRAMOCHEM and CalaChem. 'Chemicals have become
a major focus for us. With our subsidiaries, we are already seeing very
positive results, and we believe there is great potential in pharmaceutical
and plant protection chemistry,' said Dr. Dirk Markus, CEO of AURELIUS AG.
'With our two specialty chemical subsidiaries ISOCHEM and CalaChem, in the
last few years we were able to substantially improve operating results by
introducing new products and moving into new markets.'
Starting September 1, 2012 the new Briar Chemicals Ltd. will focus on
extending its product portfolio and expanding contract production for
third-party customers. Investment in a wastewater treatment plant and a
multi-production facility will assure the long-term viability of Briar
Chemicals and its approx. 250 jobs. The Group anticipates that the expanded
sales capability of its other specialty chemical subsidiaries ISOCHEM and
CalaChem will enable it to grow faster than the market in the specialty
chemical industry. 'This new autonomy is an outstanding opportunity for us
to offer development services and production of high-value chemicals to
other customers as well,' said Gerhard Engleder, responsible for the
investment in Briar Chemicals.
The divestment of the production site in Norwich is part of Bayer
CropScience's global consolidation of crop protection product
manufacturing. As an independent company, Briar Chemicals will be in an
even better position to develop its business activities. Bayer AG has
confirmed that it will continue to work closely with Briar Chemicals in the
coming years, so that production capacity utilization will remain at a high
level. For the 250 employees, this means a good outlook for the future, and
their health and safety will remain a top priority. 'The site in Norwich is
in outstanding technical condition and a leader in its field,' noted Dr.
Markus. 'We are delighted that with Bayer CropScience another well-known
company has decided to sell part of its manufacturing activities to
AURELIUS.'
About Aurelius
The AURELIUS Group specializes in acquiring companies with development
potential and providing them with operational support. With respect to the
acquisition of subsidiaries, AURELIUS strives to identify, analyze, develop
and exploit all available opportunities in the market. The AURELIUS Group
understands itself to be a GOOD HOME for its subsidiaries on a long-term
basis. Although its acquisition activities are not limited to a certain
sector, AURELIUS has placed a certain emphasis on the following sectors:
industrial enterprises, chemicals, business services, consumer goods/food&beverage and telecommunications, media&technology.
AURELIUS has many years of investment and management experience in
different industries and sectors. AURELIUS improves the performance of its
subsidiaries by providing management capacities and the necessary financial
resources for investing in innovative products, sales and research.
AURELIUS is a globally active company with offices in Munich and London and
subsidiaries in Germany, Great Britain, France, Poland, Hungary, the
Netherlands, Switzerland, Norway, Belgium, Luxembourg, Slovakia and
Slovenia, as well as the United States, China, Malaysia, India, Thailand
and South Korea. The shares of AURELIUS AG are traded in the Open Market
segment of the Frankfurt Stock Exchange and the m:access of the Munich
Stock Exchange under ISIN DE000A0JK2A8. Additional information can be found
at www.aureliusinvest.de.
Contact
Investor Relations&Corporate Communications
Phone +49 (89) 544799 - 0
Fax +49 (89) 544799 - 55
investor(at)aureliusinvest.de
End of Corporate News
---------------------------------------------------------------------
03.09.2012 Dissemination of a Corporate News, transmitted by DGAP - a
company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
183886 03.09.2012
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 03.09.2012 - 09:00 Uhr
Sprache: Deutsch
News-ID 179640
Anzahl Zeichen: 5056
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 259 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: AURELIUS becomes major player on the specialty chemical market"
steht unter der journalistisch-redaktionellen Verantwortung von
AURELIUS AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
